key: cord-0707948-yqg0la69
authors: Ozsurekci, Yasemin; Aykac, Kubra; Er, Ahmet Gorkem; Halacli, Burcin; Arasli, Mehmet; Oygar, Pembe Derin; Gürlevik, Sibel; Cura Yayla, Burcu Ceylan; Karakaya, Jale; Alp, Alparslan; Topeli, Arzu; Cengiz, Ali Bülent; Akova, Murat; Ceyhan, Mehmet
title: Predictive value of cytokine/chemokine responses for the disease severity and management in children and adult cases with COVID‐19
date: 2020-12-01
journal: J Med Virol
DOI: 10.1002/jmv.26683
sha: a3b2dcd658aafde921011b0f633552d4adad5c6d
doc_id: 707948
cord_uid: yqg0la69

The disease course of children with coronavirus disease 2019 (COVID‐19) seems milder as compared with adults, however, actual reason of the pathogenesis still remains unclear. There is a growing interest on possible relationship between pathogenicity or disease severity and biomarkers including cytokines or chemokines. We wondered whether these biomarkers could be used for the prediction of the prognosis of COVID‐19 and improving our understanding on the variations between pediatric and adult cases with COVID‐19. The acute phase serum levels of 25 cytokines and chemokines in the serum samples from 60 COVID‐19 pediatric (n = 30) and adult cases (n = 30) including 20 severe or critically ill, 25 moderate and 15 mild patients and 30 healthy pediatric (n = 15) and adult (n = 15) volunteers were measured using commercially available fluorescent bead immunoassay and analyzed in combination with clinical data. Interferon gamma‐induced protein 10 (IP‐10) and macrophage inflammatory protein (MIP)−3β levels were significantly higher in patient cohort including pediatric and adult cases with COVID‐19 when compared with all healthy volunteers (p ≤ .001 in each) and whereas IP‐10 levels were significantly higher in both pediatric and adult cases with severe disease course, MIP‐3β were significantly lower in healthy controls. Additionally, IP‐10 is an independent predictor for disease severity, particularly in children and interleukin‐6 seems a relatively good predictor for disease severity in adults. IP‐10 and MIP‐3β seem good research candidates to understand severity of COVID‐19 in both pediatric and adult population and to investigate possible pathophysiological mechanism of COVID‐19.

Despite its worldwide spread, childhood data on the disease caused by the virus, called 2019 novel coronavirus (2019-nCoV) (coronavirus disease 2019 ) are even more limited, with many uncertainties particularly regarding its clinical course as compared with adults. Although there are many different comorbid conditions and underlying diseases in children, unlike other viruses, COVID-19 causes less disease and progresses better in children in worldwide. [1] [2] [3] [4] [5] [6] In fact, while many diseases in the childhood, particularly in children under 2 years of age tend to have a more severe and complicated course. However, serious complication besides fatal outcome of children with COVID-19 is also less than adults with COVID-19 and there is no explanation on where this difference might have arisen in children as compared with adults. [7] [8] [9] [10] The causal relationship between pathogenicity or disease severity and biomarkers is still unclear in many studies. To understand the milder course of children, which have an immature immune system, the need for antigenic stimulation and sequential changes in the functional capacity of lymphocytes should be reviewed. Additionally, excessive immune responses during the infection, called as cytokine storm, have been found to be associated with high cytokine levels and widespread tissue damage. 11 A couple of studies have shown that cytokine storm may have occurred in patients with COVID-19. 2, 12 Interleukin-1B (IL-1B), IL-1RA, IL-7, IL-8, IL-9, IL-10, fibroblast growth factor, granulocyte colony-stimulating factor, granulocyte-macrophage colonystimulating factor, interferon γ (IFN-γ), interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein (MCP-1), macrophage inflammatory protein (MIP)−1A, MIP-1B, platelet derived growth factor, tumor necrosis factor α (TNF-α) and vascular endothelial growth factor were studied in an adult study consist of 41 patients with COVID-19 and found to be higher in patients compared to healthy individuals. Moreover, the IL-2, IL-7, IL-10, GCSF, IP-10, MCP-1, MIP-1A, and TNF-α levels were higher in patients hospitalized in the intensive care unit (ICU). 2 Pierce et al. 13 investigated the reasons for the differences of clinical outcome in pediatric versus adult patients with COVID-19 and reported that pediatric patients with COVID-19 who had milder clinical course had lower IL-6, TNF-α, and IP-10 concentrations compared to adults with severe outcome. Conversely, the levels of IL-17A and IFN-γ were higher in patients aged under 24 years versus adults and this difference was found to be age-related, particularly for IL-17A. We wondered whether these biomarkers could be used in the diagnosis of COVID-19 or in predicting its prognosis. Therefore, in this study, it was planned to study cytokines and members of the chemokine family in children and adults diagnosed with COVID-19. Thus, we aimed to understand the differences between pediatric and adult patients and whether the prognosis can be predicted with the help of these biomarkers in addition to conventional methods. Serum samples were taken from pediatric and adult cases with   COVID-19 at the admission and the symptom days of pediatric   and adult cases before admission was median 2 

The severity of pediatric COVID-19 cases, based on the clinical characteristics and the results of laboratory examinations and radiologic imaging, as defined by Dong et al., 8 

Categorical variables are presented as per frequencies and in percentages and were compared using the χ 2 test. Continuous variables are presented as median (min-max) and differences in continuous variables between the groups were tested by using the Mann-Whitney U test. Kruskal-Wallis test was used to compare the plasma cytokine or chemokine levels among the mild, moderate, severe, and critical groups. After Kruskal-Wallis test, the Dunn's test was used to determine the differences between the groups. Receiver-operating characteristic (ROC) curve and area under the ROC curve (AUC) of serum cytokine or chemokine levels was estimated for the patients with severe disease course or not. Moreover, a logistic regression model was established with IP-10, MIF 1β, and MIP-3β variables. The combined values (score) for the prediction of developing severe disease was calculated using binary logistic regression. ROC analysis was performed for these combined values. All statistical tests were calculated using SPSS 22.0 for Windows (IBM). p Value of less than .05 was considered statistically significant. When the parameters of pediatric patients with COVID-19 and healthy children were evaluated according to disease course, the IP10 and MIP-3β levels differed significantly between the groups (p = .008 and p = .002, respectively) ( Table 3 ). The IP-10 levels were higher in pediatric patients with severe/critical disease course (757.5 ± 1212.7) compared to healthy controls (176.3 ± 245.7, p = .004). The MIP-3β levels were higher in patients with moderate disease course (2079.5 ± 609.1) compared to healthy controls (684.8 ± 784.6, p = .001). When compared to adult patients according to disease severity, the I-TAC, IP-10, MIP-3β, and IL-6 levels differed significantly between the groups (p = .031, p ≤ .001, p = .028, and p = .001, respectively) ( Table 4 ). The I-TAC levels were higher in adult patients with severe/critical disease course (23.7 ± 250) compared to healthy controls (p = .027). The IP-10 levels were lower in healthy controls (26.2 ± 116.5) compared to adult patients with moderate disease (629.9 ± 353.9, p ≤ .001) and adult patients with severe disease course (655.8 ± 512.6, p = .001). The MIP-3β levels were higher in severe adult COVID-19 cases (1242.2 ± 589.6) compared to healthy controls (561.3 ± 773, p = .047). The IL-6 levels were higher in adult patients with severe disease (2399.9 ± 877.1) compared to healthy controls (1107.9 ± 760.8, p = .001).

We further analyzed whether these cytokines or chemokines could be used as predictors for the disease severity of COVID-19.

These patients were divided into the severe group, which contained the severe and critically ill cases, and the non-severe group, which included mild and moderate cases. The ROC curve of cytokines which was determined as significant was calculated using the expression levels in both children and adult cases. The results of (p = .06) ( Figure 1C ). Combination of the four cytokines or chemokines in adults showed the AUC of 0.78 (p = .01) ( Figure 1D ). All the p values for other cytokines were higher than .05.

We found that IP-10 levels were significantly higher in both pediatric and adult cases with severe disease course and MIP-3β were significantly lower in healthy controls. Additionally, our data showed IP-10 is an independent predictor for disease severity, particularly in children. IP-10 and MIP-3β seem promising targets not only for Uncontrolled proinflammatory responses, which is called as cytokine storm, induce an important immunopathology and is one of the main reasons of the disease severity during the viral infections. 28 Accordingly, not only the causative microorganisms but also the pathogen induced cytokine storm should be considered during the treatment course. 16 Severe disease outcome including death caused by cytokine storm could be downregulated by corticosteroids. 29 Although high dose corticosteroids have been shown to be associated with an increase in mortality and longer viral shedding in flu cases due to H7N9, use of corticosteroids at low-to-moderate was found to be associated with reduced mortality in pneumonia caused by viruses such as influenza and 2019-nCoV. 30 IL-6 and IL-1α seem to be the crucial therapeutic targets in patients with COVID-19 in this study. Accordingly, IL-6, although is not significant, seems to be a good predictor for disease severity, particularly in adult cases. There are several ongoing studies with the different anti-cytokine therapies including IL-1 and IL-6 blockade in severe cases. 35 It was reported in observational studies on tocilizumab that it decreases fever, systemic inflammation and associates with decreased risk of intubation and mortality. [36] [37] [38] [39] [40] [41] reported that 72% of the cases with COVID-19 who received anakinra experienced clinical improvement and showed significantly higher survival rate as compared with the historical control group and patients treated with anakinra had a significantly lower risk of death and need of mechanical ventilation than the controls in another study. 43 A couple of studies about sepsis, it was also reported that short-term, high dose anakinra treatment in patients with severe sepsis did not increase the bacterial superinfection risk, which is a great concern in patients with COVID-19 as well. 44, 45 Nevertheless, the use of clinical judgement is crucial for the management of the cases because of variations of the background antivirals or immunomodulators for accurate interpretation of these results across both patients and studies.

Some several limitations of this study should be noted. First, the sample sizes were relatively small. The frequencies of patients with fatal outcome and the disease severity seem comparable between children and adults in this cohort, which is not consistent with most published studies; because our pediatric centers were tertiary care referral centers with high quality PICU facility in the capital of the Turkey. Therefore, our result cannot be generalized and need to be confirmed in larger cohort to reveal the actual disease nature.

Second, detailed analyses of lymphocyte subgroups could not be performed simultaneously at the beginning of the pandemic period.

However, we believe that our data will guide the physicians and ameliorate our understanding on the possible physio-pathological pathway of COVID-19.

As a conclusion, we compared the differences of cytokine/chemokine profiles between pediatric and adult cases with COVID-19, particularly according to disease severity and found that IP-10 and MIP-3β might be the significant predictors for the disease as well as the severity. Therefore, our findings let us understand roughly the mechanisms of the disease course of COVID-19 and help to figure out possible new-aged treatment modalities to cope with cytokine storm in COVID-19, such as global targeting of the inflammation or neutralizing a single key inflammatory mediator. Because the activation of a viral antigen-specific Th1 immune response is vital for COVID-19

protection, chemokines, such as MIP-1α, and MIP-3β seem likely promising immuno-adjuvant candidates for further vaccine studies.

Department with the number of THD-2020-18774.

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical characteristics of coronavirus disease 2019 in China

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention

Members of the COVID-19 surveillance group. characteristics of COVID-19 patients dying in Italy

CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States

Novel coronavirus infection in hospitalized infants under 1 year of age in China

Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China

Clinical and CT features in pediatric patients with COVID-19 infecton: Different points from adults

Coronavirus infections in children including COVID-19. an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children

Acute respiratory distress syndrome

2019-novel coronavirus (2019-nCoV) infections trigger and exaggerated cytokine response aggravating lung injury

Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients

Clinical Management of COVID-19: Interim Guidance

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of covıd-19

Exuberant elevation of IP-10, MCP-3 and IL-1 ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome. medRxiv

Effects of MIP-1α, MIP-1β, and MIP-3β on the induction of HIV Gag-specific immune response with DNA vaccines

Cytokine/chemokine responses in activated CD4 + and CD8 + T cells isolated from peripheral blood, bone marrow, and axillary lymph nodes during acute simian immunodeficiency virus infection

The role of dendritic cells in the innate immune system

Dendritic cells and the control of immunity

T-cell mediated immune response to respiratory coronaviruses

Synthesis of the CCchemokines MIP-1alpha, MIP-1beta, and RANTES is associated with a type 1 immune response

Requirements of MIP-1alpha for an inflammatory response to viral infection

Macrophage-derived chemokine (MDC/CCL22) is a novel mediator of lung inflammation following hemorrhage and resuscitation

Elevated expression of TARC (CCL17) and MDC (CCL22) in models of cigarette smoke-induced pulmonary inflammation

The immunology of multisystem inflammatory syndrome in children with COVID-19

Endothelial cell infection and andothelitis in COVID-19

Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

Antiinflammatory action of glucocorticoidsnew mechanism for old drugs

Adjuvant corticosteroid treatment in adults with influenza A (H7N9) viral pneumonia

On the use of corticosteroids for 2019-nCoV pneumonia

Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience

National influenza A(H1N1)pdm09 clinical investigation group of China, effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. Influenza Other Respir Viruses

Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis

Role for anti-cytokine therapies in severe coronavirus disease

Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19

Effective treatment of severe COVID-19 patients with tocilizumab

HNF Hospital Tocilizumab multidisciplinary team. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in

Tocilizumab for the treatment of severe coronavirus disease 2019

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Anakinra for severe forms of COVID-19: A cohort study

IL-1RA sepsis syndrome study group, Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled multicenter trial. The interleukin-1 receptor antagonist sepsis investigator group

Predictive value of cytokine/chemokine responses for the disease severity and management in children and adult cases with COVID-19

The authors declare that there are no conflict of interests.

Dr. Ozsurekci 

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

http://orcid.org/0000-0001-8662-6909Kubra Aykac https://orcid.org/0000-0002-0974-4765Pembe Derin Oygar https://orcid.org/0000-0002-8612-4586